Please login to the form below

Not currently logged in
Email:
Password:

NicOx strengthens R&D organisation through new hires

NicOx has hired Dr Pascal Pfister as CSO

French biopharmaceutical company NicOx has hired Dr Pascal Pfister as Chief Scientific Officer (CSO).

Dr Pfister will report to Michele Garufi, Chairman and CEO, and will have overall responsibility for NicOx's R&D activities, notably the research, regulatory affairs, clinical development and drug development departments.

Pfister brings extensive experience and leadership to NicOx from his 19 year career at Novartis and Sandoz. Pfister's previous management career includes 19 years at Novartis & Sandoz Pharmaceuticals in France, Switzerland and in the US, where he has occupied positions of growing responsibility in a range of therapeutic fields, including the inflammatory and cardiometabolic disease areas.

Pfisterís most recent position was vice-president of global therapeutic area head for respiratory and dermatology, clinical development and medical affairs, where he was responsible for managing a large team across the EU, the UK and the US.

NicOx has also further strengthened its R&D team through the appointment of Dr Jacques Djian as cardiometabolic leader, who will advise and manage NicOx' R&D in this area.

Dr Djian comes to NicOx with 16 years of experience in the pharmaceutical industry and was previously the senior scientific consultant for cardiovascular and metabolic disease issues at Novartis.

Djian has also worked for Wyeth Research as global senior director of the cardiovascular area and at Sanofi, where he was scientific director of clinical development.

4th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...

Infographics